美国癌症联合委员会第八版癌症分期手册中乳腺癌的主要变化
美国癌症联合委员会(AJCC)乳腺癌专家多学科团队修订第八版TNM分期,在解剖学TNM基础上纳入肿瘤分级、增殖率、雌激素与孕激素受体表达、人表皮生长因子2(HER2)表达及基因表达预后面板等生物学因素,并纳入商业基因检测的预后信息,期望为分期系统提供更高精度与灵活性。
要点
- 第八版AJCC乳腺癌分期仍以解剖学TNM因素为基础,同时纳入分级、激素受体和HER2等生物学因素。
- 肿瘤生物标志物和低Oncotype DX复发评分可改变预后和分期。
- 第八版为基于传统解剖因素的预后分类提供灵活平台,可用患者生物标志物和多因素预后面板数据修改和增强。
核心结论
- 第八版AJCC TNM分期系统为基于传统解剖因素的预后分类提供了灵活平台,可用患者生物标志物和多因素预后面板数据修改和增强。
- 第八版仍是全球乳腺癌分期的基础,并将纳入未来在线更新以保持及时性和相关性。
研究设计与样本
- 由乳腺癌专家多学科团队确定第八版AJCC原发肿瘤、淋巴结和转移(TNM)分类的修订。
- 尽可能遵循AJCC对所有肿瘤类型的证据级别和指南。
主要发现
- 专家小组认为分期系统应继续基于TNM解剖因素以保持全球价值。
- 认识到分级、激素受体表达和HER2扩增的预后影响,要求将其纳入分期系统。
- 承认商业可用的基于基因的检测的价值,并加入预后信息。
- 肿瘤生物标志物和低Oncotype DX复发评分可改变预后和分期。
- 这些更新基于已发表信息的范围和对大型、尚未发表数据库的分析,预期为分期系统提供额外精度和灵活性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Answer questions and earn CME/CNE The revision of the eighth edition of the primary tumor, lymph node, and metastasis (TNM) classification of the American Joint Commission of Cancer (AJCC) for breast cancer was determined by a multidisciplinary team of breast cancer experts. The panel recognized the need to incorporate biologic factors, such as tumor grade, proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression prognostic panels into the staging system. AJCC levels of evidence and guidelines for all tumor types were followed as much as possible. The panel felt that, to maintain worldwide value, the tumor staging system should remain based on TNM anatomic factors. However, the recognition of the prognostic influence of grade, hormone receptor expression, and HER2 amplification mandated their inclusion into the staging system. The value of commercially available, gene-based assays was acknowledged and prognostic input added. Tumor biomarkers and low Oncotype DX recurrence scores can alter prognosis and stage. These updates are expected to provide additional precision and flexibility to the staging system and were based on the extent of published information and analysis of large, as yet unpublished databases. The eighth edition of the AJCC TNM staging system, thus, provides a flexible platform for prognostic classification based on traditional anatomic factors, which can be modified and enhanced using patient biomarkers and multifactorial prognostic panel data. The eighth edition remains the worldwide basis for breast cancer staging and will incorporate future online updates to remain timely and relevant. CA Cancer J Clin 2017;67:290-303. © 2017 American Cancer Society.
引用
- Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017. PMID: 28294295. doi:10.3322/caac.21393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。